Europe’s molecular oncology diagnostics market is transforming cancer care through next-generation sequencing, liquid biopsies, and companion diagnostics. Valued at $606 Mn in 2024 and projected to reach $1532.4 Mn by 2033, this sector is driving precision medicine forward despite challenges in cost, reimbursement, and regulation. 

Join Chris on Deep Tech Talk as we explore how cutting-edge diagnostics are reshaping cancer treatment across Europe.